FR2479690A1 - Medicament utile notamment pour le traitement de l'arthrite et son procede d'obtention par extraction des feuilles et rhizomes de polypodiaceae - Google Patents
Medicament utile notamment pour le traitement de l'arthrite et son procede d'obtention par extraction des feuilles et rhizomes de polypodiaceae Download PDFInfo
- Publication number
- FR2479690A1 FR2479690A1 FR8106562A FR8106562A FR2479690A1 FR 2479690 A1 FR2479690 A1 FR 2479690A1 FR 8106562 A FR8106562 A FR 8106562A FR 8106562 A FR8106562 A FR 8106562A FR 2479690 A1 FR2479690 A1 FR 2479690A1
- Authority
- FR
- France
- Prior art keywords
- rhizomes
- leaves
- polar
- extract
- polar solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000008569 process Effects 0.000 title claims abstract description 15
- 238000000605 extraction Methods 0.000 title claims abstract description 11
- 241000196124 Polypodiaceae Species 0.000 title claims abstract description 6
- 206010003246 arthritis Diseases 0.000 title description 8
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 7
- 238000003825 pressing Methods 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- 238000005342 ion exchange Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 3
- 239000012634 fragment Substances 0.000 claims abstract 2
- 239000011343 solid material Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 241000985694 Polypodiopsida Species 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- -1 anionic ion Chemical class 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical group [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 241001362811 Niphidium Species 0.000 claims description 2
- 241001518160 Pleopeltis Species 0.000 claims description 2
- 241001518143 Polypodium <fern> Species 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 241000366676 Justicia pectoralis Species 0.000 claims 1
- 241001362938 Microgramma Species 0.000 claims 1
- 229940124347 antiarthritic drug Drugs 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 5
- 230000002456 anti-arthritic effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000005352 clarification Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000004090 etiopathogenesis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001116734 Campyloneurum Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005885 boration reaction Methods 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003562 lightweight material Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 235000021178 picnic Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES490293A ES8104315A1 (es) | 1980-04-02 | 1980-04-02 | Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2479690A1 true FR2479690A1 (fr) | 1981-10-09 |
| FR2479690B1 FR2479690B1 (enrdf_load_stackoverflow) | 1984-11-02 |
Family
ID=8480183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8106562A Granted FR2479690A1 (fr) | 1980-04-02 | 1981-04-01 | Medicament utile notamment pour le traitement de l'arthrite et son procede d'obtention par extraction des feuilles et rhizomes de polypodiaceae |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR224063A1 (enrdf_load_stackoverflow) |
| AU (1) | AU538973B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1176173A (enrdf_load_stackoverflow) |
| DE (1) | DE3111056A1 (enrdf_load_stackoverflow) |
| ES (1) | ES8104315A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2479690A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2075834A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2088770B1 (es) * | 1995-02-23 | 1997-03-16 | Esp Farmaceuticas Centrum Sa | Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
| US5614197A (en) * | 1995-02-13 | 1997-03-25 | Industrial Farmaceutica Cantabria, S.A. | Polypodium extract as photoprotectant |
| ES2137900B1 (es) * | 1998-06-02 | 2000-08-16 | Helsint S A L | Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos. |
| ES2124675B1 (es) * | 1997-07-30 | 1999-10-01 | Helsint S A L | "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida". |
| WO1999006058A1 (es) * | 1997-07-30 | 1999-02-11 | Helsint, S.A.L. | Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer |
| US6228366B1 (en) * | 1998-07-29 | 2001-05-08 | Helsint, S.A.L. | Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients |
| ES2146555B1 (es) * | 1999-01-22 | 2001-03-01 | Helsint S A L | Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR611156A (fr) * | 1925-07-17 | 1926-09-22 | Procédé d'extraction des principes biologiques actifs de l'extrait éthéré de racine de fougère mâle | |
| US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
| FR2426471A1 (fr) * | 1978-05-24 | 1979-12-21 | Conrad Ltd | Procede d'obtention de terpenes naturels presentant une activite antipsoriasique |
| FR2434819A1 (fr) * | 1978-07-07 | 1980-03-28 | Conrad Ltd | Fraction polaire naturelle, utile notamment comme antipsoriasique, et son procede de preparation |
-
1980
- 1980-04-02 ES ES490293A patent/ES8104315A1/es not_active Expired
-
1981
- 1981-03-20 DE DE3111056A patent/DE3111056A1/de not_active Withdrawn
- 1981-03-25 AR AR284728A patent/AR224063A1/es active
- 1981-03-26 GB GB8109495A patent/GB2075834A/en not_active Withdrawn
- 1981-03-31 AU AU68934/81A patent/AU538973B2/en not_active Expired - Fee Related
- 1981-04-01 FR FR8106562A patent/FR2479690A1/fr active Granted
- 1981-04-01 CA CA000374387A patent/CA1176173A/en not_active Expired
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR611156A (fr) * | 1925-07-17 | 1926-09-22 | Procédé d'extraction des principes biologiques actifs de l'extrait éthéré de racine de fougère mâle | |
| US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
| FR2426471A1 (fr) * | 1978-05-24 | 1979-12-21 | Conrad Ltd | Procede d'obtention de terpenes naturels presentant une activite antipsoriasique |
| FR2434819A1 (fr) * | 1978-07-07 | 1980-03-28 | Conrad Ltd | Fraction polaire naturelle, utile notamment comme antipsoriasique, et son procede de preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
Also Published As
| Publication number | Publication date |
|---|---|
| AR224063A1 (es) | 1981-10-15 |
| DE3111056A1 (de) | 1982-02-11 |
| FR2479690B1 (enrdf_load_stackoverflow) | 1984-11-02 |
| ES490293A0 (es) | 1981-04-16 |
| AU538973B2 (en) | 1984-09-06 |
| AU6893481A (en) | 1981-10-08 |
| CA1176173A (en) | 1984-10-16 |
| ES8104315A1 (es) | 1981-04-16 |
| GB2075834A (en) | 1981-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2680368A1 (fr) | Alpha-glycosyl-quercetine, son procede de preparation et ses utilisations. | |
| WO2009141524A1 (fr) | Procede d'obtention d'un extrait de marc de canneberge utilisable notamment dans la prevention et le traitement d'affections telles que caries, gingivites, maux de gorge | |
| EP0349469B1 (fr) | Produit pharmaceutique doté d'activité de régénération de l'épiderme basé sur le principe actif du mimosa tenuiflora et procédé d'obtention correspondant | |
| FR2479690A1 (fr) | Medicament utile notamment pour le traitement de l'arthrite et son procede d'obtention par extraction des feuilles et rhizomes de polypodiaceae | |
| WO2022169066A1 (ko) | 금화규 유래 콜라겐아미노산을 이용한 기능성 콜라겐 조성물 | |
| LU81464A1 (fr) | Procede d'obtention d'une fraction polaire naturelle dotee d'activite anti-psoriasique | |
| CA2928542A1 (en) | Herbal composition, process for its preparation and use thereof | |
| FR2675020A1 (fr) | Produit solide contenant des composants de propolis, preparation et applications. | |
| EP0075523B1 (fr) | Nouveaux médicaments à base d'extraits d'algues, et formulations correspondantes | |
| CN1123340C (zh) | 抗过敏剂 | |
| JPS58116650A (ja) | サトウキビを原料とする強壮食品の製造法 | |
| EP2303301B1 (fr) | Compositions a base de plantes et utilisations | |
| JPH02157297A (ja) | 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤 | |
| JPH03163026A (ja) | 血管拡張剤 | |
| WO1992000085A1 (fr) | Lyophilisat de potiron doux hybride et medicaments le contenant | |
| DE60027760T2 (de) | Verwendung von substituierten nitrobenzol derivaten zur behandlung von erkrankungen verursacht von bakterien, pilzen und viren | |
| BE881595A (fr) | Inducteur d'interferon et son procede de fabrication | |
| FR2855056A1 (fr) | Medicament notamment pour le traitement de la drepanocytose ou du sida | |
| US20060167104A1 (en) | Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family and use of N,N'-dibenzylthiourea as a medicine | |
| KR100712264B1 (ko) | 치료제 | |
| CH657605A5 (fr) | Argiles modifiees, leur procede de preparation et compositions therapeutiques a base de ces argiles. | |
| WO2021260671A9 (fr) | Extrait d'un champignon de la famille des boletus fungi pour son utilisation notamment dans la prévention de la maladie covid 19 | |
| FR2855055A1 (fr) | Medicament notamment pour le traitement de la depranocytose ou du sida | |
| FR2536281A1 (fr) | Compositions pharmaceutiques permettant de reguler les fonctions phagocytaires | |
| EP4161538A1 (en) | Use of propolis obtained by special extraction method in spreadable mixtures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |